# **ORAL PRESENTATION**

# **Open Access**

# Chronic beta-adrenergic blockade prevents volume overload-induced re-localization and oxidation of soluble guanylyl cyclase

Yuchuan Liu<sup>1</sup>, Louis Dell'Italia<sup>2</sup>, Victor Rizzo<sup>1,3</sup>, Emily J Tsai<sup>1,4\*</sup>

*From* 6th International Conference on cGMP: Generators, Effectors and Therapeutic Implications Erfurt, Germany. 28-30 June 2013

## Background

While  $\beta$ -adrenergic blockade is a cornerstone of heart failure therapy, its therapeutic role in chronic mitral regurgitation remains questionable. Animal studies and a small clinical trial have demonstrated cardiac functional improvement with  $\beta_1$ -adrenoceptor blocker metoprolol in chronic mitral regurgitation [1,2]. How  $\beta_1$ AR-blockade halts functional decline of the volume-overloaded, eccentric hypertrophied heart is not well understood; anti-oxidant effects of  $\beta$ -blockade ( $\beta$ B) may play a role. We recently demonstrated that volume-overload cardiac stress induces re-localization and microdomain-specific oxidation of the nitric oxide receptor soluble guanylyl cyclase (sGC) in the failing heart [3,4]. Given that nitric oxide-cyclic guanosine monophosphate (NO-cGMP) modulates cardiac contractility and protects against cardiac hypertrophy, we hypothesized that  $\beta_1$ AR-blockade prevents oxidation of sGC and promotes myocardial NO-cGMP signaling in a microdomain-specific fashion.

### Materials and methods

Volume-overload (VO) was established by chordal ruptureinduced mitral regurgitation (MR) in mongrel dogs. Some dogs were treated with metoprolol succinate (100mg orally once daily; MR+  $\beta$ B). Expression, localization, cyclase activity, and redox state of myocardial sGC were assessed in Control, MR, and MR+ $\beta$ B dogs.

#### Results

 $sGC\alpha_1$  and  $-\beta_1$  subunits were detected within and outside of caveolae-enriched lipid rafts (Cav3<sup>+</sup>LR). In MR,

\* Correspondence: emily.tsai@tuhs.temple.edu

<sup>1</sup>Cardiovascular Research Center, Temple University School of Medicine, Philadelphia, PA, 19140, USA

Full list of author information is available at the end of the article



total sGC $\alpha_1$  expression fell to nearly 50% of Control and re-localized away from Cav3<sup>+</sup>LR to non-lipid raft microdomains (NLR). While overall  $sGC\beta_1$  expression was also less in MR+ $\beta$ B, caveolae-localization of sGC $\beta_1$ was preserved. Overall NO-responsiveness of sGC remained intact in MR hearts, irrespective of BB therapy. However, a potentiated response to heme/NO-independent sGC activator BAY 60-2770 suggested that a subset of sGC was heme-oxidized in MR but not in Control or MR+ $\beta$ B. Moreover, differential responses to BAY 60-2770 and NO were noted in Cav3<sup>+</sup>LR and NLR microdomains. In Control hearts, responses to BAY 60-2770 and NO were similar within respective microdomains, suggesting a predominantly reduced form of sGC in both Cav3<sup>+</sup>LR and NLR of Controls. In contrast, BAY 60-2770 response of NLR-localized sGC was potentiated in MR but not in MR+ $\beta$ B hearts, suggesting that  $\beta$ B therapy prevented oxidation of NLR-localized sGC. Moreover, BAY 60-2770 responses of Cav3<sup>+</sup>LR-localized sGC were not potentiated in any hearts, suggesting an anti-oxidation protection associated with caveolae-localization. These changes in caveolae-localization and redox state of sGC were also reflected by microdomain distribution of VASP phosphorylation.

#### Conclusion

 $\beta_1AR$  blocker mediated cardioprotection in the volumeoverloaded heart is associated with enhanced microdomain specific myocardial NO-cGMP signaling, both within and outside of caveolae. Such prevention of volume overload-induced spatial and redox dysregulation of myocardial sGC suggests novel strategies to enhancing cardioprotective NO-cGMP signaling.

© 2013 Liu et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

#### Authors' details

<sup>1</sup>Cardiovascular Research Center, Temple University School of Medicine, Philadelphia, PA, 19140, USA. <sup>2</sup>Division of Cardiovascular Disease, Department of Medicine, University of Alabama Birmingham School of Medicine, Birmingham, AL, 35233, USA. <sup>3</sup>Department of Anatomy and Cell Biology, Temple University School of Medicine, Philadelphia, PA, 19140, USA. <sup>4</sup>Section of Cardiology, Department of Medicine, Temple University School of Medicine, Philadelphia, PA, 19140, USA.

#### Published: 29 August 2013

#### References

- Pat B, Killingsworth C, Denney T, Zheng J, Powell P, Tillson M, Dillon AR, Dell'Italia LJ: Dissociation between cardiomyocyte function and remodeling in beta-adrenergic receptor blockade in isolated canine mitral regurgitation. Am J Physiol Heart Circ Physiol 2008, 295:H2321-H2327.
- Ahmed MI, Aban I, Lloyd SG, Gupta H, Howard G, Inusah S, Peri K, Robinson J, Smith P, McGiffin DC, Schiros CG, Denney T Jr, Dell'Italia LJ: A randomized controlled phase IIb trial of beta(1)-receptor blockade for chronic degenerative mitral regurgitation. J Am Coll Cardiol 2012, 60:833-838.
- Tsai EJ, Liu Y, Koitabashi N, Bedja D, Danner T, Jasmin JF, Lisanti MP, Friebe A, Takimoto E, Kass DA: Pressure-overload induced subcellular relocalization/oxidation of soluble guanylyl cyclase in the heart modulates enzyme stimulation. *Circ Res* 2012, 110:295-303.
- Liu Y, Dillon AR, Tillson M, Makarewich C, Nguen V, Dell'Italia L, Sabria A, Rizzo V, Tsai EJ: Volume overload induces differential spatiotemporal regulation of myocardial soluble guanylyl cyclase in eccentric hypertrophy and heart failure. J Mol Cell Cardiol 2013, 60:72-83.

#### doi:10.1186/2050-6511-14-S1-O22

**Cite this article as:** Liu *et al.*: Chronic beta-adrenergic blockade prevents volume overload-induced re-localization and oxidation of soluble guanylyl cyclase. *BMC Pharmacology and Toxicology* 2013 **14**(Suppl 1):O22.

# Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

BioMed Central

Submit your manuscript at www.biomedcentral.com/submit